One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System.

ABSTRACT:

Objective

In September 2016, the U.S. Food and Drug Administration approved the Medtronic 670G "hybrid" closed-loop system. In Auto Mode, this system automatically controls basal insulin delivery based on continuous glucose monitoring data but requires users to enter carbohydrates and blood glucose for boluses. To track real-world experience with this first commercial closed-loop device, we prospectively followed pediatric and adult patients starting the 670G system.

Research design and methods

This was a 1-year prospective observational study of patients with type 1 diabetes starting the 670G system between May 2017 and May 2018 in clinic.

Results

Of the total of 84 patients who received 670G and consented, 5 never returned for follow-up, with 79 (aged 9-61 years) pr

SUBMITTER: Lal RA 

PROVIDER: S-EPMC6868462 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature